MedTrace Logo

Pilot Study of Lisdexamfetamine for Treatment of Cocaine Dependence

NCT01490216 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2019-07-15

No results posted yet for this study

Summary

The purpose of this study is to evaluate ideal dose or lisdexamfetamine and tolerability, plus reduction in cocaine use and craving.

Conditions

  • Cocaine Dependence

Interventions

DRUG

lisdexamfetamine

20mg q.d. to 70mg b.i.d

Sponsors & Collaborators

Principal Investigators

  • Marc E Mooney, Ph.D. · University of Minnesota

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-07-31
Primary Completion
2013-01-31
Completion
2013-01-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01490216 on ClinicalTrials.gov